Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

News and Trends 2 Dec 2014

Ascendis Pharma Closed €48M for an Innovative Weekly Hormone Injection

Ascendis Pharma, a biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, raised €48 million for a Serie D financing. This financing is expected to be used to fund late-stage clinical trials of TransCon Growth Hormone for the treatment of growth hormone deficiency (GHD). Growth hormone deficiency, is a serious orphan disease affecting both […]

December 2, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 1 Dec 2014

The First Gene Therapy Drug Will Be Sold at Record €1,1M Price

What could you buy with €1,1M euros? A house? Or a single prescription for a new drug… The first gene therapy drug “Glybera” is set to go on sale in Germany with a €1.1 million price tag, a new record for a medicine to treat a rare disease. And this drug from UniQure is not the only one […]

December 1, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 28 Nov 2014

One Billion Strategic Oncology Alliance for the Second Largest Antibody Technology Platform

Oxford BioTherapeutics and Menarini Group have initiated the first-in-human clinical study of OBT357, a novel enhanced antibody for the treatment of acute myeloid leukemia (AML). This is the first of five development programs between the two companies to enter the clinic in a $1 billion strategic oncology alliance. Oxford BioTherapeutics and the Menarini Group established their […]

November 28, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 27 Nov 2014

Curetis Raised Additional €14.5M to Diagnose Severe Infectious Diseases

Curetis AG, a developer of next-level molecular diagnostic solutions, has closed a EUR 14.5 million extension of its Series B financing round, which was originally led by HBM Partners in April 2013. Curetis is a young, dynamic and creative molecular diagnostics company. They are specialized in the diagnosis of severe infectious diseases in hospitalized patients. The company helps to combat […]

November 27, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 26 Nov 2014

The Highest Ever Bioavailable Curcumin is Coming in Europe

Theravalues Corporation, Tokyo based company, will launch Theracurmin® Super for the European market at Hi Europe 2014, an event which will take place in Amsterdam at the beggining of December. Curcumin is a turmeric derivative, which is the pigment that gives its yellow-orange color to curry. It is a compound that has been the subject of many studies, […]

November 26, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 25 Nov 2014

Promethera Biosciences Raised €25,33M to Treat Liver Diseases

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, raised 25,33 million euros. The major innovation of Promethera HepaStem is based on Heterologous Human Adult Liver Progenitor Cells (HHALPC). It is a potential to treat a wide variety of congenital […]

November 25, 2014 - 2 minutesmins - By Julie Lellouche

ADVERTISEMENT

News and Trends 24 Nov 2014

Will New Actavis-Allergan Entity Lead to Be in the World Top 10 Drugmakers Companies?

The US pharmaceutical company Allergan, known for their Botox, agreed an Actavis bid of 53 billion euros, they permanently passed up the proposition of Valeant Pharmaceuticals International and the activist investor William Ackman. The Allergan-Actavis entity will have a diversified portfolio of medicines and generic, especially in dermatology, gynecology and ophthalmology. It should generate about […]

November 24, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 23 Nov 2014

Munich: Why is it One of the Best Biotech Cluster in Europe ?

The biotech sector in the Greater Munich area continues to demonstrate significant growth in revenue and staff numbers despite ever-increasing international competition. This continues Munich’s status as one of the pre-eminent locations for this future-oriented industry. This was confirmed by the latest study carried out by the City of Munich, the IHK and BioM based […]

November 23, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 22 Nov 2014

After AstraZeneca Turned Down Pfizer’s Bid, Merck Took the Opportunity

Pharmaceutical giants Merck and Pfizer have agreed a deal to develop and market immunotherapy agents to fight cancer. Now, the last Pfizer’s proposal to AstraZeneca is pending. Merck will get an upfront payment of €682 million from the U.S. drugmaker for sharing rights to develop its experimental immunotherapy drug with Pfizer. It is also eligible […]

November 22, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 18 Nov 2014

Is France Leading the European Synthetic Biology-Based Biofuel Field?

France has great Synthetic Biology Biotech companies. Paris-based Global Bioenergies carried out the first isobutene production trial in its industrial pilot of Pomacle-Bazancourt in the east of France. Two other companies, Deinove and Fermentalg are growing extremely fast, and giant Total is investing massively in the field. Is France on the good way to become […]

November 18, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 15 Nov 2014

Why do Servier bets one Billion euros on Revolutionary Diabetes Drugs Delivery Device?

The French company Servier wants to invest one billion euros by a partnering with the American company Intarcia regarding their subcutaneous implant for diabetes. This is a breakthrough micropump, the first device without injection able to deliver the molecule Exenatide during one year. It is a huge step forward in treating type 2 diabetes. Indeed, most people forget […]

November 15, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 14 Nov 2014

Onxeo confirms receipt of the $25M milestone payment from its US partner Spectrum

Onxeo, an innovative company specializing in the development of orphan oncology drugs, founded after the merger of BioAlliance Pharma and Topotarget, announces that it has received from his US partner Spectrum Pharmaceuticals the milestone payment of $25 million related to the approval of Beleodaq by the FDA. Early July 2014, Beleodaq was granted by the […]

November 14, 2014 - 3 minutesmins - By Joachim Eeckhout

ADVERTISEMENT